Telomir Pharmaceuticals (NASDAQ: TELO) announced the submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration for Telomir-1 (Telomir-Zn), targeting advanced and metastatic triple-negative breast cancer (TNBC). The submission is supported by preclinical efficacy and safety data demonstrating tumor growth reduction and favorable tolerability. Pending IND clearance, the company plans to initiate a Phase 1/2 clinical trial evaluating the oral therapy, with a focus on safety, dose optimization, and early signs of antitumor activity.
Triple-negative breast cancer is an aggressive subtype that accounts for approximately 10–15% of all breast cancers and is characterized by the lack of estrogen, progesterone, and HER2 receptors, limiting treatment options. Telomir-1 represents a novel epigenetic approach aimed at addressing significant unmet need in this patient population. The therapy is designed to modulate intracellular metal homeostasis, redox balance, epigenetically regulated gene expression, mitochondrial function, and genomic stability.
According to the press release, Telomir Pharmaceuticals is a preclinical-stage biotechnology company developing small-molecule therapeutics targeting fundamental epigenetic and metabolic mechanisms implicated in cancer, aging, and degenerative disease. The company's lead program, Telomir-1, has demonstrated activity in preclinical studies. The IND submission marks a critical step toward clinical development, and if cleared, the Phase 1/2 trial will assess safety, tolerability, and preliminary efficacy in patients with advanced TNBC.
For more details, the full press release is available at https://ibn.fm/CgUik. Investors can find the latest news and updates relating to TELO in the company's newsroom at https://ibn.fm/TELO.
The announcement underscores the potential of Telomir-1 to offer a new therapeutic option for patients with TNBC, a disease with limited treatment alternatives. The company's focus on epigenetic mechanisms distinguishes it from conventional approaches, potentially providing a novel way to combat cancer cell growth and resistance. As Telomir Pharmaceuticals advances toward the clinic, the oncology community will be watching for initial safety and efficacy data from the planned trial.
